Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 2/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | PTPRC | P08575 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5099195 | 1.00 | MME (0.54) | MMEALDH1A1LTA4HACECTSK | |
| SCHEMBL7364893 | 0.86 | MME (0.52) | MMELTA4HACECTSKFOLH1 | |
| SCHEMBL7364890 | 0.86 | MME (0.52) | MMELTA4HACECTSKFOLH1 | |
| SCHEMBL9417473 | 0.84 | GPR34 (0.62) | MMEACE | |
| SCHEMBL85084 | 0.83 | CAPN1 (0.52) | MMEACE | |
| SCHEMBL3301559 | 0.82 | ALDH1A1 (0.50) | ALDH1A1PTPRCPTPN1 | |
| SCHEMBL2368090 | 0.81 | PSMB8 (0.64) | MMELTA4HACEFOLH1 | |
| SCHEMBL2368096 | 0.81 | PSMB8 (0.64) | MMELTA4HACEFOLH1 | |
| SCHEMBL15251753 | 0.81 | PSMB8 (0.64) | MMELTA4HACEFOLH1 | |
| SCHEMBL4553474 | 0.81 | FOLH1 (0.56) | MMELTA4HCTSKFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030144175-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-07-31 | — | — | US | claimed |
| CN-1350458-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2002-05-22 | — | — | CN | claimed |
| US-7405209-B2 | e.g. 2-Benzyloxycarbonylamino-4-methyl-pentanoyl)-3-oxo-azepan-4-ylcarbamoyl}carbamic acid benzyl ester; protease inhibitors like cathepsin K; osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-29 | — | — | US | disclosed |
| CN-1253441-C | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2006-04-26 | — | — | CN | disclosed |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION | 2005-11-17 | — | — | US | disclosed |
| EP-1307204-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2004-06-02 | — | — | EP | disclosed |
| EP-1384713-A1 | 4-amino-azepan-3-one derivatives as protease inhibitors | SmithKline Beecham Corporation (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20040002487-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2004-01-01 | — | — | US | disclosed |
| US-20030225061-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2003-12-04 | — | — | US | disclosed |
| CN-1444481-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2003-09-24 | — | — | CN | disclosed |
| US-20030144175-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-07-31 | — | — | US | disclosed |
| EP-1307204-A1 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-05-07 | — | — | EP | disclosed |
| US-20020147188-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | disclosed |
| CN-1350458-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2002-05-22 | — | — | CN | disclosed |
| EP-1158986-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-03-27 | — | — | EP | disclosed |
| WO-2001095911-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |
| EP-1158986-A1 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000038687-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225061-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | MME 120/4885ALDH1A1 3651/4885LTA4H 578/4885 |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | CTSK, CTSZ, CTSE | MME 516/4885ALDH1A1 3117/4885LTA4H 798/4885 |
| US-20020147188-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | MME 120/4885ALDH1A1 3651/4885LTA4H 578/4885 |
| US-20040002487-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | MME 120/4885ALDH1A1 3651/4885LTA4H 578/4885 |
| US-20030144175-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | MME 120/4885ALDH1A1 3651/4885LTA4H 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.